[ad_1]
Dr. Santosh Kesari, Principal Investigator, Oversees Open Neurological & Mind Most cancers Medical Trials
Dr. Santosh Kesari of the Pacific Neuroscience Institute is the principal investigator for greater than a dozen medical trials, of which 8 are mind tumor-related. Dr. Kesari is the Chair and Professor of the Division of Translational Neuro-oncology and Neurotherapeutics at Saint John’s Most cancers Institute. He’s ranked among the many prime 1 % of neuro-oncologist and neurologists within the nation, in line with Fortress Connolly Medical Ltd, and is an internationally acknowledged scientist and clinician.
Remodeling biomedical analysis and drugs into promising new therapies used clinically begins right here at Saint John’s Most cancers Institute.
Ongoing Trials for Mind Tumors, Neuroscience
Caris Biorepository Analysis Protocol
Advancing precision drugs for sufferers
Abstract:
The Caris Biorepository is a group of organic specimens together with medical and demographic knowledge that can be used and shared for analysis. Caris Life Sciences will preserve the info and specimens, and management entry to info and specimens. That is an observational, group research.
Trial Goal:
The target is to develop and implement a state-of-the-science biorepository, offering important biospecimens and knowledge to inside researchers and exterior analysis companions. Collaborators embrace authorities, educational establishments, and different trade companies will work collectively to advance drug growth discoveries, which helps to information different analysis trials and future healthcare insurance policies.
Estimated variety of contributors: 100,000
Begin Date: November 2010
Finish Date: November 2020
Conclusion of the research: November 2025
Link to Study at clinicaltrials.gov
Caris Molecular Intelligence® and Caris Facilities of Excellence for Precision Medication NetworkTM Outcomes Related Repository
Advancing precision drugs for sufferers
Abstract:
Effecting change in illness therapy processes by advancing precision drugs and enhancing look after most cancers via buying and sharing worthwhile molecular tumor profiling info and medical outcomes in a collaborative, safe surroundings.
Caris Life Sciences and Precision Oncology Alliance Retrospective Outcomes-Related Database
Advancing precision drugs for sufferers
Abstract:
This repository is a multi-center, outcomes research designed to retrospectively accumulate knowledge on the demographics, presentation, analysis, therapy, value of related care, high quality of life, and outcomes of topics using Caris Molecular Intelligence® (CMI) Companies for the therapy of most cancers. Previous to enrolling a topic, the doctor could have made the unbiased choice whether or not or to not make the most of the drug associations offered by CMI and made medical therapy decisions as acceptable. Thus, knowledge captured and reported offers a “actual world” perspective on analysis, therapy, value, and outcomes
A Longitudinal Evaluation of Tumor Evolution in Affected person with Mind Most cancers
Assessing the protection of medicine in sufferers with mind most cancers
Abstract:
The aim of this research is to check the protection and tolerability of sure medication when given to sufferers after surgical procedure, and earlier than receiving radiation therapy and temozolomide (a chemotherapy treatment). The trial focuses on sufferers with newly recognized, high-grade glioma—a tumor that happens within the mind and spinal wire and develops from specialised cells that assist neurons.
Trial Goal:
The target of this research to find out if there can be any unwanted side effects (good or dangerous) as a result of drug combos whereas evaluating any preliminary proof of anti-cancer exercise. The trial may also look at tumor traits by accumulating mind tumor tissue samples, measuring the variety of medication in biospecimens, and assessing biomarkers.
Estimated variety of contributors: 90
Begin Date: March 1, 2018
Finish Date: March 1, 2022
Conclusion of the research: March 2022
Link to Study at clinicaltrials.gov
Open-label Examine Investigating of OKN-007 Mixed With Temozolomide in Sufferers With Recurrent Glioblastoma
Advancing precision drugs for sufferers
Abstract:
This Section II research investigates how the physique tolerates, absorbs, and removes properties of OKN-007, a drug which will cease tumor development by blocking enzymes wanted for cell development. The trial targets sufferers with recurring malignant mind tumors known as glioblastomas, which develop from particular mind cells known as astrocytes. Sufferers are required to have been beforehand handled, together with with surgical procedure, radiation remedy, chemotherapy, and in some instances, therapy for recurrent illness.
Trial Goal:
To measure neurologic perform and efficiency, opposed occasions, and accumulate blood plasma for future research.
Estimated variety of contributors: 56
Begin Date: June 12, 2020
Finish Date: Might 25, 2022
Conclusion of the research: October 25, 2022
Link to Study at clinicaltrials.gov
Liquid Biopsy Analysis Of Biomarkers In Varied Medical Specimen Varieties From Sufferers With Most cancers
Advancing precision drugs for sufferers
Abstract:
Liquid biopsy specimen collections can be obtained prospectively from a number of clinics for the analysis of varied non-blood bodily fluid pattern varieties resembling cerebrospinal fluid (CSF), pleural fluid, bronchial washings, ascites fluid, amniotic fluid, saliva, sputum, urine, and many others. The research is meant to evaluate the feasibility of interrogating these pattern varieties for molecular profiling with Biocept Goal Selector™ liquid biopsy methodologies which might be both provided on the corporate’s present business check menu or are in growth. Prospectively collected blood samples may also be collected from sufferers for the aim of medical validation of recent Biocept Goal Selector™ assays and/or most cancers varieties that aren’t on the corporate’s present business check menu.
A Multicenter, Open-Label Examine with a Randomized Management Arm of the Efficacy, Security, and Pharmacokinetics of Intravenously Infused Berubicin in Grownup Sufferers with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Commonplace First-Line Remedy
Advancing precision drugs for sufferers
Abstract:
A research of Berubicin in grownup topics with recurrent glioblastoma multiforme
Trial Goal:
After relapse or failure of their preliminary therapy, sufferers with glioblastoma will both obtain investigational therapy with Berubicin (an anti-cancer drug) or commonplace therapy with lomustine oral chemotherapy. Sufferers can be randomized to therapy teams and are two occasions extra prone to obtain Berubicin. Comparisons of total response and survival outcomes can be evaluated to find out efficacy and security.
Estimated variety of contributors: 210
Begin Date: Might 18, 2021
Finish Date: October 2024
Conclusion of the research: February 2025
Link to Study at clinicaltrials.gov
Neurological Outcomes in Well being and Illness
Advancing precision drugs for sufferers
Abstract:
This can be a non-therapeutic, non-interventional, potential research. A complete evaluation of systematically collected useful and anatomical imaging modalities, histopathology, genotyping, profiling, and medical knowledge will permit for higher prediction of consequence, optimization of therapy, and in the end, customized therapy of mind tumors and neurological problems.
A Pivotal, Randomized, Open-label Examine of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Remedy of Newly Identified Glioblastoma
Advancing precision drugs for sufferers
Abstract:
To check the effectiveness and security of Optune® (a wearable, FDA-approved therapy for glioblastoma) given along with radiation remedy and temozolomide (a sort of chemotherapy for mind tumors) in newly recognized glioblastoma sufferers, in comparison with radiation remedy and temozolomide alone. Optune® and upkeep temozolomide is sustained following radiation remedy.
Estimated variety of contributors: 950
Begin Date: December 8, 2020
Finish Date: August 2024
Conclusion of the research: August 2026
Link to Study at clinicaltrials.gov
Potential Non-interventional research in sufferers with domestically superior or metastatic TRK fusion most cancers handled with larotrectinib (Potential Non-interventional Examine in Sufferers with Regionally Superior or Metastatic TRK Fusion Most cancers Handled with Larotrectinib)
Advancing precision drugs for sufferers
Abstract:
This observational research seeks to evaluate the protection and effectiveness of larotrectinib (a cancer-inhibiting treatment) in sufferers with domestically superior or metastatic TRK fusion most cancers. Sufferers who’ve determined to deal with with larotrectinib could have the chance to be adopted all through the length of their therapy to analyze unwanted side effects, response, and basic outcomes.
Estimated variety of contributors: 300
Begin Date: April 3, 2020
Finish Date: November 30, 2029
Conclusion of the research: March 31, 2030
Link to Study at clinicaltrials.gov
A Section 1/2 Examine of PBI-200 in Topics with NTRK-Fusion-Constructive Superior or Metastatic Stable Tumors
Advancing precision drugs for sufferers
Abstract:
This primary-in-human research investigates the protection and tolerability of PBI-200, a novel oral remedy developed with very excessive TRK selectivity to deal with superior or metastatic cancers that categorical the NTRK gene fusion, NTRK amplification, or EWSR1-WT1 fusion. In Section 1 of this research, the dose can be incrementally elevated to find out which is the most secure and handiest. As soon as the really helpful dose is established the research will proceed to Section 2 through which additional investigation of PBI-200’s antitumor exercise will happen.
Section 1 trial of intravenous administration of TAEKVAC- HerBy vaccine alone and together with HER2 antibodies in sufferers with superior most cancers.
This research is a part 1 open-label vaccine (TAEK-VAC-HerBy) in sufferers with superior brachyury (a tumor-specific antigen) and/or HER2 expressing most cancers. Sufferers will obtain the vaccine intravenously each three weeks for a complete of three doses.
Estimated variety of contributors: 55
Begin Date: August 10, 2020
Finish Date: January 2024
Conclusion of the research: January 2026
Link to Study at clinicaltrials.gov
An Open-label, Nonrandomized, Section 1 Drug-Drug Interplay Examine to Consider the Pharmacokinetics of Belinostat in Mixture with Atazanavir in Sufferers with Superior Relapsed/Refractory Stable Tumors or Hematological Malignancies
Advancing precision drugs for sufferers
Abstract:
Sufferers with superior strong tumors which have exhausted commonplace salvage remedy choices will obtain a complete of two cycles of belinostat infusions, an authorised therapy for relapsed/refractory peripheral T-cell lymphoma. An oral antiretroviral treatment, atazanavir, can be given together and evaluated for potential drug-to-drug interactions with belinostat.
Expanded Entry to ONC201 for Sufferers With H3 K27M-mutant and/or Midline Excessive-Grade Gliomas.
That is an expanded entry research that goals to offer eligible sufferers of medical neuroendocrine trial ONC201 with an anti-cancer compound that targets small oncology molecules. Eligible sufferers could be required to current with certainly one of; a). glioma that’s constructive for the H3 K27M mutation, b). grade III or IV glioma involving the thalamus, hypothalamus, brainstem, cerebellum, midbrain, or spinal wire; or c). diffuse intrinsic pontine glioma (DIPG).
Link to Study at clinicaltrials.gov
Pemetrexed for the Remedy of Chordoma
The aim of this research is to check the protection and tolerability of Pemetrexed—a chemical compound used to deal with sure sorts of cancers—administered to individuals with chordoma (a uncommon kind of cancerous tumor that may happen wherever alongside the backbone). This research may also assess the unwanted side effects, development, and traits of most cancers cells, and evaluate biomarkers to measure illness development.
Estimated variety of contributors: 15
Begin Date: September 6, 2019
Finish Date: Might 31, 2022
Conclusion of the research: Might 31, 2023
Link to Study at clinicaltrials.gov
Principal Investigator:
Chair, Division of Translational Neurosciences
Director of Neuro-oncology
Pacific Neuroscience Institute
Saint John’s Most cancers Institute
The Saint John’s Most cancers Institute maintains a strong biospecimen tissue financial institution and has demonstrated sustained scientific high quality, assets, and storage programs for the efficient administration of human tissues.
To take part in a trial, please name:
310-582-7448
Concerning the Creator
[ad_2]
Source link
Discussion about this post